Corporate Profile

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids. The Company’s TRACERTM discovery platform is identifying improved vectors selected to target desired tissues and cells with greater specificity, at lower doses, and with reduced risk of off-target effects compared to conventional AAV. Proprietary TRACER capsids are powering the Company’s early-stage programs and licensing opportunities. With a deep roster of experienced biopharmaceutical leaders and specialized expertise in gene therapy, the Voyager team is working relentlessly to develop new capsids that will enable safe and effective delivery of genetic payloads that could change the trajectory of disease and life as we know it for millions of people.

More Information